Large-Scale Trial Of Vaginal Ring That Releases Anti-HIV Drug Announced At Health Summit In London

“This week, at the Pacific Health Summit in London, the final large-scale trial was officially launched of a vaginal ring which women can wear and forget about — at least for a month at a time — while it releases an HIV virus-killing drug called dapivirine,” the Guardian reports. “If successful, it could also be combined with hormonal contraception,” the newspaper notes. The phase III clinical trial, “launched by the International Partnership for Microbicides, is already recruiting women in South Africa, Rwanda and Malawi” and “will involve 1,650 women — enough to prove definitively whether it works,” according to the newspaper (Boseley, 6/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.